BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, Do RKG, Ehman EC, Fowler KJ, Hussain HK, Jha RC, Karam AR, Mamidipalli A, Marks RM, Mitchell DG, Morgan TA, Ohliger MA, Shah A, Vu KN, Sirlin CB; LI-RADS Evidence Working Group. Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. Radiology 2018;286:29-48. [PMID: 29166245 DOI: 10.1148/radiol.2017170554] [Cited by in Crossref: 131] [Cited by in F6Publishing: 128] [Article Influence: 26.2] [Reference Citation Analysis]
Number Citing Articles
1 Fischer H, Goltz D. Hepatozelluläre Karzinome und leberzellähnliche Tumoren. Pathologe 2019;40:101-18. [DOI: 10.1007/s00292-018-0565-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Shin J, Lee S, Yoon JK, Chung YE, Choi J, Park M. LI‐RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis. J Magn Reson Imaging 2021;54:518-25. [DOI: 10.1002/jmri.27570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL; JBCR., Ai3. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Breast Cancer Res Treat 2022. [PMID: 35262831 DOI: 10.1007/s10549-022-06521-7] [Reference Citation Analysis]
4 Marks RM, Masch WR, Chernyak V. LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology 2021;216:295-304. [DOI: 10.2214/ajr.20.24272] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zheng W, Huang H, She D, Xiong M, Chen X, Lin X, Cao D. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol (NY) 2022;47:957-68. [PMID: 34964069 DOI: 10.1007/s00261-021-03380-6] [Reference Citation Analysis]
6 Noordam L, Ge Z, Özturk H, Doukas M, Mancham S, Boor PPC, Campos Carrascosa L, Zhou G, van den Bosch TPP, Pan Q, IJzermans JNM, Bruno MJ, Sprengers D, Kwekkeboom J. Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2499. [PMID: 34065388 DOI: 10.3390/cancers13102499] [Reference Citation Analysis]
7 Dregely I, Prezzi D, Kelly-Morland C, Roccia E, Neji R, Goh V. Imaging biomarkers in oncology: Basics and application to MRI. J Magn Reson Imaging 2018;48:13-26. [PMID: 29969192 DOI: 10.1002/jmri.26058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
8 Lacroix M, Mulé S, Herin E, Pigneur F, Richard P, Zegai B, Baranes L, Djabbari M, Brunetti F, de'Angelis N, Laurent A, Tacher V, Kobeiter H, Luciani A. Virtual unenhanced imaging of the liver derived from 160-mm rapid-switching dual-energy CT (rsDECT): Comparison of the accuracy of attenuation values and solid liver lesion conspicuity with native unenhanced images. Eur J Radiol 2020;133:109387. [PMID: 33166833 DOI: 10.1016/j.ejrad.2020.109387] [Reference Citation Analysis]
9 Yi D, Wen-Ping W, Lee WJ, Meloni MF, Clevert DA, Cristina Chammas M, Tannapfel A, Forgione A, Dietrich CF. Hepatocellular carcinoma in the non-cirrhotic liver. Clin Hemorheol Microcirc 2021. [PMID: 34842182 DOI: 10.3233/CH-211309] [Reference Citation Analysis]
10 Vernuccio F, Cannella R, Porrello G, Calandra A, Midiri M, Furlan A, Brancatelli G. Uncommon imaging evolutions of focal liver lesions in cirrhosis. Abdom Radiol (NY) 2019;44:3069-77. [PMID: 31222462 DOI: 10.1007/s00261-019-02101-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
12 Kim SW, Joo I, Kim H, Ahn SJ, Kang H, Jeon SK, Lee JM. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020;30:2861-70. [DOI: 10.1007/s00330-019-06623-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
13 Gao F, Wei Y, Zhang T, Jiang H, Li Q, Yuan Y, Yao S, Ye Z, Wan S, Wei X, Nie L, Tang H, Song B. New Liver MR Imaging Hallmarks for Small Hepatocellular Carcinoma Screening and Diagnosing in High-Risk Patients. Front Oncol 2022;12:812832. [PMID: 35356206 DOI: 10.3389/fonc.2022.812832] [Reference Citation Analysis]
14 Kwee SA, Tiirikainen M, Sato MM, Acoba JD, Wei R, Jia W, Le Marchand L, Wong LL. Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma. Cancer Res 2019;79:1696-704. [PMID: 30760520 DOI: 10.1158/0008-5472.CAN-18-3837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
15 Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS): Use of Gadoxetate Disodium and LI-RADS. J Magn Reson Imaging 2019;49:1236-52. [DOI: 10.1002/jmri.26540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
16 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Kang HJ, Lee JM, Jeon SK, Jang S, Park S, Joo I, Yoon JH, Han JK. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI. Eur Radiol 2021;31:824-33. [PMID: 32845387 DOI: 10.1007/s00330-020-07162-4] [Reference Citation Analysis]
18 Dong SY, Yang YT, Wang WT, Zhu S, Sun W, Zeng MS, Rao SX. Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology. Acta Radiol 2022;63:734-42. [PMID: 33969700 DOI: 10.1177/02841851211014194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kang JH, Choi SH, Byun JH, Kim DH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim P. Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging. Eur Radiol 2020;30:2881-9. [DOI: 10.1007/s00330-019-06645-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Heverhagen JT, Kudrnová S. Subcentimeter Hepatocellular Carcinoma: A New Paradigm for Treatment with Percutaneous Radiofrequency Ablation? Radiology 2018;288:887-8. [PMID: 29916779 DOI: 10.1148/radiol.2018180977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Millet JD, Kamaya A, Choi HH, Dahiya N, Murphy PM, Naveed MZ, O’boyle M, Parra LA, Perez MG, Pirmoazen AM, Rodgers SK, Wasnik AP, Maturen KE. ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. Journal of the American College of Radiology 2019;16:1656-62. [DOI: 10.1016/j.jacr.2019.05.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
22 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 204] [Article Influence: 76.7] [Reference Citation Analysis]
23 Caraiani C, Boca B, Bura V, Sparchez Z, Dong Y, Dietrich C. CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together? Biology (Basel) 2021;10:412. [PMID: 34066607 DOI: 10.3390/biology10050412] [Reference Citation Analysis]
24 Min JH, Kim JM, Kim YK, Kim H, Cha DI, Kang TW, Choi GS, Choi SY, Ahn S. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 2021. [PMID: 34242468 DOI: 10.1111/liv.15012] [Reference Citation Analysis]
25 Kim YY, Kim YK, Min JH, Cha DI, Kim JM, Choi GS, Ahn S. Intraindividual Comparison of Hepatocellular Carcinoma Washout between MRIs with Hepatobiliary and Extracellular Contrast Agents. Korean J Radiol 2021;22:725-34. [PMID: 33660458 DOI: 10.3348/kjr.2020.1143] [Reference Citation Analysis]
26 Kim MY, Joo I, Kang HJ, Bae JS, Jeon SK, Lee JM. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 2020;45:2440-8. [PMID: 32382817 DOI: 10.1007/s00261-020-02545-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
27 Ren A, Zhao P, Yang D, Du J, Wang Z, Yang Z. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017: LI-RADS v2018 of MRI for Diagnosing HCC. J Magn Reson Imaging 2019;50:746-55. [DOI: 10.1002/jmri.26640] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
28 Fung A, Shanbhogue KP, Taffel MT, Brinkerhoff BT, Theise ND. Hepatocarcinogenesis: Radiology-Pathology Correlation. Magn Reson Imaging Clin N Am 2021;29:359-74. [PMID: 34243923 DOI: 10.1016/j.mric.2021.05.007] [Reference Citation Analysis]
29 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
30 Gupta S, Rajiah P, Middlebrooks EH, Baruah D, Carter BW, Burton KR, Chatterjee AR, Miller MM. Systematic Review of the Literature: Best Practices. Acad Radiol 2018;25:1481-90. [PMID: 30442379 DOI: 10.1016/j.acra.2018.04.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Jiang H, Song B, Qin Y, Chen J, Xiao D, Ha HI, Liu X, Oloruntoba-Sanders O, Erkanli A, Muir AJ, Bashir MR. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 2021;31:3638-48. [PMID: 33245494 DOI: 10.1007/s00330-020-07488-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cannella R, Calandra A, Cabibbo G, Midiri M, Tang A, Brancatelli G. Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation. European Journal of Radiology 2019;120:108689. [DOI: 10.1016/j.ejrad.2019.108689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Dietrich CF, Tana C, Caraiani C, Dong Y. Contrast enhanced ultrasound (CEUS) imaging of solid benign focal liver lesions. Expert Rev Gastroenterol Hepatol. 2018;12:479-489. [PMID: 29658347 DOI: 10.1080/17474124.2018.1464389] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
34 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kim SS, Hwang JA, Shin HC, Choi S, Kang TW, Jou SS, Lee WH, Park S, Heo NH. LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy? Eur Radiol 2019;29:186-94. [DOI: 10.1007/s00330-018-5657-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
36 Ludwig DR, Romberg EK, Fraum TJ, Rohe E, Fowler KJ, Khanna G. Diagnostic performance of Liver Imaging Reporting and Data System (LI-RADS) v2017 in predicting malignant liver lesions in pediatric patients: a preliminary study. Pediatr Radiol 2019;49:746-58. [DOI: 10.1007/s00247-019-04358-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
37 Li JP, Zhao S, Jiang HJ, Jiang H, Zhang LH, Shi ZX, Fan TT, Wang S. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00135-7. [PMID: 35729000 DOI: 10.1016/j.hbpd.2022.06.003] [Reference Citation Analysis]
38 Alhasan A, Cerny M, Olivié D, Billiard JS, Bergeron C, Brown K, Bodson-Clermont P, Castel H, Turcotte S, Perreault P, Tang A. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol (NY) 2019;44:517-28. [PMID: 30167771 DOI: 10.1007/s00261-018-1762-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
39 Hajjo R, Sabbah DA, Bardaweel SK, Tropsha A. Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML). Diagnostics (Basel) 2021;11:742. [PMID: 33919342 DOI: 10.3390/diagnostics11050742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lee SM, Lee JM, Ahn SJ, Kang H, Yang HK, Yoon JH. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI. Radiology 2019;292:655-63. [DOI: 10.1148/radiol.2019182867] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
41 Dietrich CF, Potthoff A, Helmberger T, Ignee A, Willmann JK; on behalf of the CEUS LI-RADS Working Group. Standardisierte Befundung und Dokumentation der Kontrastmittelsonografie der Leber (CEUS LI-RADS). Z Gastroenterol 2018;56:499-506. [DOI: 10.1055/s-0043-124874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Thibodeau-Antonacci A, Petitclerc L, Gilbert G, Bilodeau L, Olivié D, Cerny M, Castel H, Turcotte S, Huet C, Perreault P, Soulez G, Chagnon M, Kadoury S, Tang A. Dynamic contrast-enhanced MRI to assess hepatocellular carcinoma response to Transarterial chemoembolization using LI-RADS criteria: A pilot study. Magn Reson Imaging 2019;62:78-86. [PMID: 31247250 DOI: 10.1016/j.mri.2019.06.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
43 Park EJ, Son JH, Choi SH. Imaging features of hepatocellular carcinoma in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis. Abdom Radiol (NY) 2022;47:2089-98. [PMID: 35389074 DOI: 10.1007/s00261-022-03499-0] [Reference Citation Analysis]
44 Son J, Hwang SH, Park S, Han K, Chung YE, Choi J, Kim M, Park M. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA. Investigative Radiology 2019;54:494-9. [DOI: 10.1097/rli.0000000000000562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
45 Pan F, Do TD, Vollherbst DF, Pereira PL, Richter GM, Faerber M, Weiss KH, Mehrabi A, Kauczor HU, Sommer CM. Percutaneous Irreversible Electroporation for Treatment of Small Hepatocellular Carcinoma Invisible on Unenhanced CT: A Novel Combined Strategy with Prior Transarterial Tumor Marking. Cancers (Basel) 2021;13:2021. [PMID: 33922067 DOI: 10.3390/cancers13092021] [Reference Citation Analysis]
46 Vogl TJ, Mader C, Michalik S, Hammerstingl R, Koch V. [Small hepatocellular carcinoma : Diagnostics according to guidelines and established in the clinical setting]. Radiologe 2022. [PMID: 35037980 DOI: 10.1007/s00117-021-00965-6] [Reference Citation Analysis]
47 Tsurusaki M, Sofue K, Onishi H, Goshima S, Higaki A, Isoda H, Haradome H, Ishii K, Murakami T. Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study. Jpn J Radiol 2021;39:165-77. [PMID: 33025339 DOI: 10.1007/s11604-020-01052-x] [Reference Citation Analysis]
48 Kim M, Lee S, An C. Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma. Eur Radiol 2019;29:5101-10. [DOI: 10.1007/s00330-019-06030-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
49 Liang Y, Xu F, Wang Z, Tan C, Zhang N, Wei X, Jiang X, Wu H. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma. Eur J Radiol 2022;153:110356. [PMID: 35623312 DOI: 10.1016/j.ejrad.2022.110356] [Reference Citation Analysis]
50 Schima W, Heiken J. LI-RADS v2017 for liver nodules: how we read and report. Cancer Imaging. 2018;18:14. [PMID: 29690933 DOI: 10.1186/s40644-018-0149-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
51 Lennartz S, Große Hokamp N, Zäske C, Zopfs D, Bratke G, Glauner A, Maintz D, Persigehl T, Chang DH, Hickethier T. Virtual monoenergetic images preserve diagnostic assessability in contrast media reduced abdominal spectral detector CT. Br J Radiol 2020;93:20200340. [PMID: 32644824 DOI: 10.1259/bjr.20200340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Jeon SK, Joo I, Lee DH, Lee SM, Kang HJ, Lee KB, Lee JM. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2019;29:373-382. [PMID: 29955948 DOI: 10.1007/s00330-018-5605-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
53 Abdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd El-Wahab R. Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know. J Comput Assist Tomogr. 2020;44:168-177. [PMID: 32195795 DOI: 10.1097/rct.0000000000000995] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 11.5] [Reference Citation Analysis]
54 Cannella R, Fowler KJ, Borhani AA, Minervini MI, Heller M, Furlan A. Common pitfalls when using the Liver Imaging Reporting and Data System (LI-RADS): lessons learned from a multi-year experience. Abdom Radiol (NY) 2019;44:43-53. [PMID: 30073400 DOI: 10.1007/s00261-018-1720-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
55 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
56 Cerny M, Bergeron C, Billiard JS, Murphy-Lavallée J, Olivié D, Bérubé J, Fan B, Castel H, Turcotte S, Perreault P, Chagnon M, Tang A. LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features. Radiology 2018;288:118-28. [PMID: 29634435 DOI: 10.1148/radiol.2018171678] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 14.8] [Reference Citation Analysis]
57 Shi GZ, Chen H, Zeng WK, Gao M, Wang MZ, Zhang HT, Shen J. R2* value derived from multi-echo Dixon technique can aid discrimination between benign and malignant focal liver lesions. World J Gastroenterol 2021; 27(12): 1182-1193 [PMID: 33828393 DOI: 10.3748/wjg.v27.i12.1182] [Reference Citation Analysis]
58 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
59 Wakabayashi T, Ouhmich F, Gonzalez-Cabrera C, Felli E, Saviano A, Agnus V, Savadjiev P, Baumert TF, Pessaux P, Marescaux J, Gallix B. Radiomics in hepatocellular carcinoma: a quantitative review. Hepatol Int. 2019;13:546-559. [PMID: 31473947 DOI: 10.1007/s12072-019-09973-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
60 Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2019;17:1228-38. [DOI: 10.1016/j.cgh.2018.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
61 Elmohr MM, Chernyak V, Sirlin CB, Elsayes KM. Liver Imaging Reporting and Data System Comprehensive Guide: MR Imaging Edition. Magn Reson Imaging Clin N Am 2021;29:375-87. [PMID: 34243924 DOI: 10.1016/j.mric.2021.05.012] [Reference Citation Analysis]
62 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology 2020;72:1654-65. [PMID: 32017165 DOI: 10.1002/hep.31159] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 28.5] [Reference Citation Analysis]
64 Razik A, Malla S, Goyal A, Gamanagatti S, Kandasamy D, Das CJ, Sharma R, Gupta AK. Unusual Primary Neoplasms of the Adult Liver: Review of Imaging Appearances and Differential Diagnosis. Curr Probl Diagn Radiol 2020:S0363-0188(20)30194-8. [PMID: 33199074 DOI: 10.1067/j.cpradiol.2020.10.001] [Reference Citation Analysis]
65 Wang M, Fu F, Zheng B, Bai Y, Wu Q, Wu J, Sun L, Liu Q, Liu M, Yang Y, Shen H, Kong D, Ma X, You P, Li X, Tian F. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data. Br J Cancer 2021. [PMID: 34365472 DOI: 10.1038/s41416-021-01511-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Kim SS, Lee S, Choi JY, Lim JS, Park MS, Kim MJ. Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas. Abdom Radiol (NY) 2020;45:3743-54. [PMID: 32377757 DOI: 10.1007/s00261-020-02562-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
67 Richardson ML, Amini B, Beckmann NM, Subhawong TK. Measuring and Teaching Confidence Calibration Among Radiologists: A Multi-Institution Study. J Am Coll Radiol 2020;17:1314-21. [PMID: 32739415 DOI: 10.1016/j.jacr.2020.06.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Cerny M, Chernyak V, Olivié D, Billiard J, Murphy-lavallée J, Kielar AZ, Elsayes KM, Bourque L, Hooker JC, Sirlin CB, Tang A. LI-RADS Version 2018 Ancillary Features at MRI. RadioGraphics 2018;38:1973-2001. [DOI: 10.1148/rg.2018180052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
69 Mettikanont P, Kalluri A, Bittermann T, Phillips N, Loza B, Rosen M, Siegelman E, Furth E, Abt P, Olthoff K, Shaked A, Hoteit M, Reddy KR. The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated with Explant Pathology: A Single Center Experience. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.02.005] [Reference Citation Analysis]
70 Waninger JJ, Green MD, Cheze Le Rest C, Rosen B, El Naqa I. Integrating radiomics into clinical trial design. Q J Nucl Med Mol Imaging 2019;63:339-46. [PMID: 31527581 DOI: 10.23736/S1824-4785.19.03217-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Tang ES, Hall G, Yu D, Menard A, Hopman W, Nanji S. Predictors and Cumulative Frequency of Hepatocellular Carcinoma in High and Intermediate LI-RADS Lesions: A Cohort Study from a Canadian Academic Institution. Ann Surg Oncol 2019;26:2560-7. [PMID: 31025229 DOI: 10.1245/s10434-019-07386-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Krampitz GW, Aloia TA. Staging of Biliary and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:663-83. [DOI: 10.1016/j.soc.2019.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1646] [Cited by in F6Publishing: 1401] [Article Influence: 411.5] [Reference Citation Analysis]
74 Lee HS, Kim MJ, An C. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 2019;29:2408-16. [PMID: 30552477 DOI: 10.1007/s00330-018-5893-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
75 Kim YY, Choi JY, Sirlin CB, An C, Kim MJ. Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS). Eur Radiol 2019;29:1124-32. [PMID: 30116960 DOI: 10.1007/s00330-018-5641-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
76 Lueg J, Knebel F, Awwad I, Lerchbaumer MH, Fahlenkamp U, Lembcke A, Pohlan J. Atypical presentation of a locally advanced hepatocellular carcinoma: Extensive workup of an incidental finding on computed tomography performed for planning of transcatheter aortic valve implantation. Radiol Case Rep 2021;16:2112-8. [PMID: 34158905 DOI: 10.1016/j.radcr.2021.05.021] [Reference Citation Analysis]
77 van der Pol CB, Dhindsa K, Shergill R, Zha N, Ferri M, Kagoma YK, Lee SY, Satkunasingham J, Wat J, Tsai S. MRI LI-RADS Version 2018: Impact of and Reduction in Ancillary Features. AJR Am J Roentgenol 2021;216:935-42. [PMID: 33534620 DOI: 10.2214/AJR.20.23031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, Kudo M, Murakami T. Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration. Cancers (Basel) 2021;13:1460. [PMID: 33806751 DOI: 10.3390/cancers13061460] [Reference Citation Analysis]
79 Hwang SH, Hong SB, Han K, Seo N, Choi JY, Lee JH, Park S, Lim YS, Kim DY, Kim SY, Park MS. A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoxetic Acid-Enhanced MRI Features. J Magn Reson Imaging 2021. [PMID: 34668595 DOI: 10.1002/jmri.27962] [Reference Citation Analysis]
80 Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzáles F, Schwartz FR, Gupta RT, Bashir MR, Furlan A, Marin D. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement. AJR Am J Roentgenol 2019;213:W57-65. [PMID: 31039012 DOI: 10.2214/AJR.18.20979] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
81 Bartnik K, Hołówko W, Rowiński O. Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. Life (Basel) 2021;11:1062. [PMID: 34685433 DOI: 10.3390/life11101062] [Reference Citation Analysis]
82 Jeong WK. [Radiologic Diagnosis of Hepatocellular Carcinoma]. Korean J Gastroenterol 2021;78:261-7. [PMID: 34824184 DOI: 10.4166/kjg.2021.138] [Reference Citation Analysis]
83 Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. J Magn Reson Imaging 2019;49:574-87. [PMID: 30102433 DOI: 10.1002/jmri.26199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
84 Polikoff A, Wessner CE, Balasubramanya R, Dulka S, Liu JB, Machado P, Savsani E, Lyshchik A, Shaw CM, Eisenbrey JR. Imaging appearance of residual HCC following incomplete trans-arterial chemoembolization on contrast-enhanced imaging. Abdom Radiol (NY) 2022;47:152-60. [PMID: 34643782 DOI: 10.1007/s00261-021-03298-z] [Reference Citation Analysis]
85 Cannella R, Ronot M, Sartoris R, Cauchy F, Hobeika C, Beaufrere A, Trapani L, Paradis V, Bouattour M, Bonvalet F, Vilgrain V, Dioguardi Burgio M. Enhancing capsule in hepatocellular carcinoma: intra-individual comparison between CT and MRI with extracellular contrast agent. Diagn Interv Imaging 2021:S2211-5684(21)00166-2. [PMID: 34284951 DOI: 10.1016/j.diii.2021.06.004] [Reference Citation Analysis]
86 Dietrich CF, Dong Y, Kono Y, Caraiani C, Sirlin CB, Cui XW, Tang A. LI-RADS ancillary features on contrast-enhanced ultrasonography. Ultrasonography 2020;39:221-8. [PMID: 32475089 DOI: 10.14366/usg.19052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals. J Viral Hepat 2019;26:893-9. [DOI: 10.1111/jvh.13103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
88 Chang SD, Cunha GM, Chernyak V. MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:329-45. [PMID: 34243921 DOI: 10.1016/j.mric.2021.05.014] [Reference Citation Analysis]
89 Yang J, Jiang H, Xie K, Bashir MR, Wan H, Huang J, Qin Y, Chen J, Lu Q, Song B. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: an intra-individual comparative study based on the Liver Imaging Reporting and Data System. European Journal of Radiology 2022. [DOI: 10.1016/j.ejrad.2022.110397] [Reference Citation Analysis]
90 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
91 Tamada D, Kromrey ML, Ichikawa S, Onishi H, Motosugi U. Motion Artifact Reduction Using a Convolutional Neural Network for Dynamic Contrast Enhanced MR Imaging of the Liver.Magn Reson Med Sci. 2020;19:64-76. [PMID: 31061259 DOI: 10.2463/mrms.mp.2018-0156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
92 Piñero F, Thompson MA, Diaz Telli F, Trentacoste J, Padín C, Mendizabal M, Colaci C, Gonzalez Campaña A, Pages J, Montal S, Barreiro M, Fauda M, Podestá G, Perotti JP, Silva M. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Ann Hepatol 2020;19:662-7. [PMID: 32683095 DOI: 10.1016/j.aohep.2020.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Baek KA, Kim SS, Shin HC, Hwang JA, Choi SY, Lee WH, Park CH, Lee HN, Heo NH. Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout? Abdom Radiol (NY) 2020;45:2705-16. [PMID: 32382820 DOI: 10.1007/s00261-020-02553-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
95 Hong CW, Park CC, Mamidipalli A, Hooker JC, Fazeli Dehkordy S, Igarashi S, Alhumayed M, Kono Y, Loomba R, Wolfson T, Gamst A, Murphy P, Sirlin CB. Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations. Eur Radiol 2019;29:5073-81. [PMID: 30809719 DOI: 10.1007/s00330-019-06058-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
96 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
97 Mak SH, Wong SMN, Chiu WHK, Chiang CL, Yip WLW, Ho HMC, Yeung SYC, Chan KHM, Lee WYV, Lee ASF. Presence of tumour capsule on contrast-enhanced CT is associated with improved outcomes of stereotactic body radiation therapy in hepatocellular carcinoma patients. Strahlenther Onkol 2022. [PMID: 34988623 DOI: 10.1007/s00066-021-01879-x] [Reference Citation Analysis]
98 Zhao X, Zhou Y, Zhang Y, Han L, Mao L, Yu Y, Li X, Zeng M, Wang M, Liu Z. Radiomics Based on Contrast-Enhanced MRI in Differentiation Between Fat-Poor Angiomyolipoma and Hepatocellular Carcinoma in Noncirrhotic Liver: A Multicenter Analysis. Front Oncol 2021;11:744756. [PMID: 34722300 DOI: 10.3389/fonc.2021.744756] [Reference Citation Analysis]
99 Hu YX, Shen JX, Han J, Mao SY, Mao RS, Li Q, Li F, Guo ZX, Zhou JH. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Front Oncol 2021;11:641195. [PMID: 33912456 DOI: 10.3389/fonc.2021.641195] [Reference Citation Analysis]
100 Lan H, Lin G, Zhong W. A meta-analysis of the added value of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm. Oncol Lett 2020;20:2739-48. [PMID: 32782590 DOI: 10.3892/ol.2020.11805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, Choi JI, Lee CH, Park HS, Lee K, Kim H, Yu E, Kang HJ, Ha SY, Kim JY, Ahn S, Jung ES, Kim BH, Han HS, Lee JM. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study. Radiology 2020;296:335-45. [PMID: 32484414 DOI: 10.1148/radiol.2020192275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
103 Ren A, Du J, Yang D, Zhao P, Wang Z, Yang Z. The role of ancillary features for diagnosing hepatocellular carcinoma on CT: based on the Liver Imaging Reporting and Data System version 2017 algorithm. Clinical Radiology 2020;75:478.e25-35. [DOI: 10.1016/j.crad.2019.08.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
105 Ogasawara N, Saitoh S, Suzuki F, Kinowaki K, Masuda J, Denpou H, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miura Y, Takano T, Kumada H. Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. Clin J Gastroenterol 2020;13:1225-32. [PMID: 32651870 DOI: 10.1007/s12328-020-01180-x] [Reference Citation Analysis]
106 Clarke CGD, Albazaz R, Smith CR, Rowe I, Treanor D, Wyatt JI, Sheridan MB, Guthrie JA. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clin Radiol 2021;76:333-41. [PMID: 33461746 DOI: 10.1016/j.crad.2020.12.007] [Reference Citation Analysis]
107 Kim JH, Yoon JH, Joo I, Lee JM. Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. J Magn Reson Imaging 2021;53:655-75. [PMID: 32700807 DOI: 10.1002/jmri.27213] [Reference Citation Analysis]
108 Yacoub JH, Elsayes KM, Fowler KJ, Hecht EM, Mitchell DG, Santillan C, Szklaruk J. Pitfalls in liver MRI: Technical approach to avoiding misdiagnosis and improving image quality: Pitfalls in Liver MRI: Technical Approach. J Magn Reson Imaging 2019;49:41-58. [DOI: 10.1002/jmri.26343] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
109 Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, Chammas MC, Chaubal N, Choi BI, Clevert DA, Cui X, Dong Y, D'Onofrio M, Fowlkes JB, Gilja OH, Huang P, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lee WJ, Lee JY, Liang P, Lim A, Lyshchik A, Meloni MF, Correas JM, Minami Y, Moriyasu F, Nicolau C, Piscaglia F, Saftoiu A, Sidhu PS, Sporea I, Torzilli G, Xie X, Zheng R. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med 2020;41:562-85. [PMID: 32707595 DOI: 10.1055/a-1177-0530] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
110 Rimola J, Sapena V, Brancatelli G, Darnell A, Forzenigo L, Mähringer-Kunz A, Paisant A, Renzulli M, Schima W, Terraz S, Valls C, Wagner M, Ayuso C, Vilgrain V, Reig M, Ronot M. Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. Hepatology 2022. [PMID: 35349760 DOI: 10.1002/hep.32494] [Reference Citation Analysis]
111 Min JH, Kim JM, Kim YK, Kang TW, Lee SJ, Choi GS, Choi SY, Ahn S. Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System. Hepatology 2018;68:2254-66. [PMID: 30070365 DOI: 10.1002/hep.30122] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
112 Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 2018;289:816-30. [PMID: 30251931 DOI: 10.1148/radiol.2018181494] [Cited by in Crossref: 212] [Cited by in F6Publishing: 196] [Article Influence: 53.0] [Reference Citation Analysis]
113 Lee MW, Lim HK. Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. World J Gastroenterol 2018; 24(46): 5215-5222 [PMID: 30581270 DOI: 10.3748/wjg.v24.i46.5215] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
114 Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-32. [PMID: 30255250 DOI: 10.1007/s00330-018-5727-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
115 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
116 Barat M, Nguyen TTL, Hollande C, Coty JB, Hoeffel C, Terris B, Dohan A, Mallet V, Pol S, Soyer P. LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI? Eur J Radiol 2021;138:109651. [PMID: 33740627 DOI: 10.1016/j.ejrad.2021.109651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Smereka P, Doshi AM, Lavelle LP, Shanbhogue K. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification. AJR Am J Roentgenol 2020;215:382-9. [PMID: 32432909 DOI: 10.2214/AJR.19.22033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
118 Cohen NA, Kingham TP. Minimally Invasive Staging Surgery for Cancer. Surgical Oncology Clinics of North America 2019;28:61-77. [DOI: 10.1016/j.soc.2018.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
119 Higuchi M, Tamaki N, Kurosaki M, Watakabe K, Osawa L, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. Clin Gastroenterol Hepatol 2019;17:2616-8. [PMID: 30502507 DOI: 10.1016/j.cgh.2018.11.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
120 Low HM, Choi JY, Tan CH. Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. Abdom Radiol (NY) 2019;44:493-508. [PMID: 30145629 DOI: 10.1007/s00261-018-1749-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
121 Fujita N, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Kakihara D, Nakayama T, Morita K, Ishimatsu K, Honda H. Hyperintense Liver Masses at Hepatobiliary Phase Gadoxetic Acid–enhanced MRI: Imaging Appearances and Clinical Importance. RadioGraphics 2020;40:72-94. [DOI: 10.1148/rg.2020190037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
122 Vernuccio F, Cannella R, Gozzo C, Greco V, Midiri M, Furlan A, Tang A, Brancatelli G. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine? Abdom Radiol (NY) 2020;45:2409-17. [PMID: 32435849 DOI: 10.1007/s00261-020-02578-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
123 Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, Chammas MC, Chaubal N, Choi BI, Clevert DA, Cui X, Dong Y, D'Onofrio M, Fowlkes JB, Gilja OH, Huang P, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lee WJ, Lee JY, Liang P, Lim A, Lyshchik A, Meloni MF, Correas JM, Minami Y, Moriyasu F, Nicolau C, Piscaglia F, Saftoiu A, Sidhu PS, Sporea I, Torzilli G, Xie X, Zheng R. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol 2020;46:2579-604. [PMID: 32713788 DOI: 10.1016/j.ultrasmedbio.2020.04.030] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 19.5] [Reference Citation Analysis]
124 Callen AL, Dupont SM, Price A, Laguna B, McCoy D, Do B, Talbott J, Kohli M, Narvid J. Between Always and Never: Evaluating Uncertainty in Radiology Reports Using Natural Language Processing. J Digit Imaging 2020;33:1194-201. [PMID: 32813098 DOI: 10.1007/s10278-020-00379-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Agnello F, Albano D, Sparacia G, Micci G, Matranga D, Toia P, La Grutta L, Grassedonio E, Lo Re G, Salvaggio G, Midiri M, Galia M. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging 2020;68:169-74. [PMID: 32836213 DOI: 10.1016/j.clinimag.2020.08.003] [Reference Citation Analysis]
126 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
127 van der Pol CB, Lim CS, Sirlin CB, Mcgrath TA, Salameh J, Bashir MR, Tang A, Singal AG, Costa AF, Fowler K, Mcinnes MD. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review. Gastroenterology 2019;156:976-86. [DOI: 10.1053/j.gastro.2018.11.020] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 31.0] [Reference Citation Analysis]
128 Mulé S, Galletto Pregliasco A, Tenenhaus A, Kharrat R, Amaddeo G, Baranes L, Laurent A, Regnault H, Sommacale D, Djabbari M, Pigneur F, Tacher V, Kobeiter H, Calderaro J, Luciani A. Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. Radiology 2020;295:562-71. [PMID: 32228294 DOI: 10.1148/radiol.2020192230] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
129 Ko A, Park HJ, Lee ES, Park SB, Kim YK, Choi SY, Ahn S. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI. Clin Radiol 2020;75:319.e1-9. [PMID: 31858990 DOI: 10.1016/j.crad.2019.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
130 Cho Y, Lee S, Park SJ. Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization. PLoS One 2021;16:e0245911. [PMID: 33513172 DOI: 10.1371/journal.pone.0245911] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Tang A, Abukasm K, Moura Cunha G, Song B, Wang J, Wagner M, Dietrich CF, Brancatelli G, Ueda K, Choi JY, Aguirre D, Sirlin CB. Imaging of hepatocellular carcinoma: a pilot international survey. Abdom Radiol (NY) 2021;46:205-15. [PMID: 32488557 DOI: 10.1007/s00261-020-02598-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Ham JH, Yu JS, Choi JM, Cho ES, Kim JH, Chung JJ. Corona enhancement can substitute enhancing capsule in the imaging diagnosis of small (≤ 3 cm) HCCs on gadoxetic acid-enhanced MRI. Eur Radiol 2021. [PMID: 33891153 DOI: 10.1007/s00330-021-07911-z] [Reference Citation Analysis]
133 Kanmaniraja D, Dellacerra G, Holder J, Erlichman D, Chernyak V. Liver Imaging Reporting and Data System (LI-RADS) v2018: Review of the CT/MRI Diagnostic Categories. Can Assoc Radiol J 2021;72:142-9. [PMID: 32063008 DOI: 10.1177/0846537119888393] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 You M, Yun S. Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis. Clinical Radiology 2019;74:406.e9-406.e18. [DOI: 10.1016/j.crad.2018.12.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
135 Kim Y, Kim M, Kim EH, Roh YH, An C. Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018. Radiology 2019;291:72-80. [DOI: 10.1148/radiol.2019181995] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
136 Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol 2019;20:1019-41. [PMID: 31270973 DOI: 10.3348/kjr.2018.0636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
137 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
139 Jiang H, Song B, Qin Y, Wei Y, Konanur M, Wu Y, Zaki IH, McInnes MDF, Lafata KJ, Bashir MR. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. J Magn Reson Imaging 2021. [PMID: 34236120 DOI: 10.1002/jmri.27824] [Reference Citation Analysis]
140 Umeda S, Kanda M, Kodera Y. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma. Expert Rev Mol Diagn 2019;19:725-38. [PMID: 31248309 DOI: 10.1080/14737159.2019.1638254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
141 Min JH, Kang TW, Kim YY, Cha DI, Kim YK, Kim SH, Sinn DH, Ha SY, Kim K. Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. Eur Radiol 2021;31:3315-25. [PMID: 33159576 DOI: 10.1007/s00330-020-07438-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 Wang CJ, Hamm CA, Savic LJ, Ferrante M, Schobert I, Schlachter T, Lin M, Weinreb JC, Duncan JS, Chapiro J, Letzen B. Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features. Eur Radiol. 2019;29:3348-3357. [PMID: 31093705 DOI: 10.1007/s00330-019-06214-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
143 Xu X, Mao Y, Tang Y, Liu Y, Xue C, Yue Q, Liu Q, Wang J, Yin Y, Yang J. Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/5334095] [Reference Citation Analysis]
144 Morshid A, Szklaruk J, Yacoub JH, Elsayes KM. Errors and Misinterpretations in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:419-36. [PMID: 34243927 DOI: 10.1016/j.mric.2021.05.008] [Reference Citation Analysis]
145 Cannella R, Vernuccio F, Sagreiya H, Choudhury KR, Iranpour N, Marin D, Furlan A. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol 2020;30:3770-81. [PMID: 32107603 DOI: 10.1007/s00330-020-06698-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, Kono Y, Sirlin CB, Tang A. LI-RADS 2017: An update. J Magn Reson Imaging 2018;47:1459-74. [PMID: 29626376 DOI: 10.1002/jmri.26027] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
147 Pagé G, Doblas S, Garteiser P, Van Beers BE. Editorial for "Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging". J Magn Reson Imaging 2021. [PMID: 34390605 DOI: 10.1002/jmri.27891] [Reference Citation Analysis]
148 Park JH, Chung YE, Seo N, Choi JY, Park MS, Kim MJ. Hepatobiliary phase signal intensity: A potential method of diagnosing HCC with atypical imaging features among LR-M observations. PLoS One 2021;16:e0257308. [PMID: 34516587 DOI: 10.1371/journal.pone.0257308] [Reference Citation Analysis]
149 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]